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ABSTRACT 
 
Rationale: Flecainide, a class Ic anti-arrhythmic, has emerged as an effective therapy in preventing 
arrhythmias in catecholaminergic polymorphic ventricular tachycardia (CPVT) patients refractory to -
adrenergic receptor blockade. It has been proposed that the clinical efficacy of flecainide in CPVT is due 
to the combined actions of direct blockade of ryanodine receptors (RyR2) and Na+ channel inhibition. 
However, there is presently no direct evidence to support the notion that flecainide blocks RyR2 Ca2+ flux 
in the physiologically-relevant (luminal-to-cytoplasmic) direction. The mechanism of flecainide action 
remains controversial. 
 
Objective: To examine in detail the effect of flecainide on the human RyR2 channel and to establish whether 
the direct blockade of physiologically-relevant RyR2 ion flow by the drug contributes to its therapeutic 
efficacy in the clinical management of CPVT. 
 
Methods and Results: Using single channel analysis we show that, even at supra-physiological 
concentrations, flecainide did not inhibit the physiologically relevant, luminal-to-cytosolic flux of cations 
through the channel. Moreover, flecainide did not alter RyR2 channel gating and had negligible effect on 
the mechanisms responsible for the sarcoplasmic reticulum (SR) charge-compensating counter current. 
Using permeabilised cardiac myocytes to eliminate any contribution of plasmalemmal Na+ channels to the 
observed actions of the drug at the cellular level, flecainide did not inhibit RyR2-dependent SR Ca2+ release. 
 
Conclusion: The principal action of flecainide in CPVT is not via a direct interaction with RyR2. Our data 
support a model of flecainide action in which Na+-dependent modulation of intracellular Ca2+ handling 
attenuates RyR2 dysfunction in CPVT. 
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Ryanodine receptor, flecainide, arrhythmia, catecholaminergic polymorphic ventricular tachycardia, 
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TPeA tetrapentyl ammonium 
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INTRODUCTION 
 
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a genetic condition 
characterised by an increased propensity to adrenergic-induced polymorphic or bidirectional VT in 
structurally normal hearts. The autosomal dominant form (CPVT1) is caused by mutations in the cardiac 
ryanodine receptor (RyR2) whilst the recessive form (CPVT2) arises from mutations in cardiac 
calsequestrin.1-3 Common to both CPVT1 and CPVT2 is dysfunctional sarcoplasmic reticulum (SR) Ca2+ 
release during periods of increased adrenergic drive (e.g. exercise or emotional stress) that triggers 
arrhythmogenic delayed afterdepolarizations (DADs) via the sodium-calcium exchanger (NCX).4 
 
-adrenergic receptor (-AR) blockers are the first line pharmacotherapy in the clinical 
management of CPVT but the approach of limiting cardiac excitability is sub-optimal and some patients 
exhibit persistent tachyarrhythmias.5,6 Flecainide, a class Ic anti-arrhythmic and potent Na+ channel blocker, 
has emerged as an effective alternative in CPVT patients refractory to -AR blockers.7-9 However, 
enthusiasm for using flecainide is tempered by the incomplete understanding of its mechanisms of action 
in the context of CPVT. Investigations of flecainide in a mouse model of CPVT2 and in genotyped CPVT1 
and 2 patients concluded that this drug’s principal mechanism of action was direct block of the open RyR2 
channel which limited augmented SR Ca2+ release through RyR2 and attenuated DAD-mediated triggered 
activity.8,10 Although plausible based on the data reported, the biophysical characterization of blockade of 
sheep RyR2 by flecainide favoured the net flow of ions through the RyR2 channel in the cytosolic-to-
luminal direction i.e. the non-physiological direction and did not establish whether flecainide inhibited the 
physiological (luminal-to-cytosolic) movement of cations through the channel.  
 
 Other groups have challenged the controversial assertion that RyR2 is the primary target of 
flecainide in CPVT. Liu et al reported that the efficacy of flecainide in the R4496C+/- RyR2 mouse model 
of CPVT1 depended on its well-characterised action on Na+ channels by increasing the threshold for 
triggered activity.11 Sikkel et al proposed that the flecainide-induced attenuation of Ca2+ wave generation 
was due predominantly to reduced cytosolic Ca2+ ensuing from modulation of the NCX/INa axis.1-3,12 The 
proposed ‘triple mode’ model of flecainide effect, which attempts to reconcile the observed actions of 
flecainide on RyR2, INa and NCX, has at its core the direct block of RyR2 by flecainide as the major 
mechanism.4,13  
 
 An important step in resolving the controversy is to demonstrate the ability of flecainide to directly 
modulate RyR2-mediated luminal-to-cytosolic ion flux. Here we report the detailed examination of the 
ability of flecainide to influence the conduction and gating properties of RyR2. At concentrations exceeding 
50 mol/L (i.e. substantially higher than would be achieved in humans via clinical dosing regimens)5,6,14, 
we demonstrate for the first time that cytosolic flecainide does not inhibit the physiologically relevant, 
luminal-to-cytosolic flux of cations through the RyR2 channel nor does it affect channel gating. Moreover, 
our data show that flecainide does not markedly inhibit essential charge compensating monovalent cation 
counter currents through either the SR K+ channel or RyR2. Consistent with these findings, flecainide did 
not inhibit RyR2-mediated Ca2+ release from the SR in permeabilised adult cardiac ventricular myocytes. 
Our data refute the proposal that the clinical effectiveness of flecainide in CPVT patients is dependent upon 
its ability to modulate SR Ca2+ release by a direct action on RyR2. 
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METHODS 
 
A detailed Methods section is available in the Online Data Supplement. 
 
Conditions for recording single hRyR2 channels. 
Single hRyR2 channels were incorporated into bilayers formed using a suspension of 
phosphatidylethanolamine (Avanti Polar Lipids) in n-decane (35 mg/ml). Bilayers were formed in a 
solution containing 610 mmol/L KCl, 20 mmol/L HEPES (pH 7.4) in both (cis (0.5 ml) and trans (1 ml)) 
chambers. Channel incorporation from the cis chamber was facilitated by the introduction of an osmotic 
gradient (using 200 μl 3 mol/L KCl). On stirring, hRyR2 incorporates in a fixed orientation such that the 
cis chamber corresponds to the cytosolic side of the channel and the trans chamber to the luminal side. 
After channel incorporation, symmetrical ionic conditions were re-instated by perfusion of the cis chamber 
with a 610 mmol/L KCl, 20 mmol/L HEPES (pH 7.4) solution. All experiments were carried out at room 
temperature (20-22°C). The effects of flecainide, propafenone and tetracaine (Sigma) were determined after 
addition of the drug to either cis or trans chambers at concentrations indicated in the text. 
 
Ventricular myocyte isolation, permeabilisation and imaging of Ca2+ sparks.  
All animal surgical procedures and peri-operative management were carried out in accordance with the 
Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH 
Publication, 8th Edition, 2011) under assurance number A5634-01. Imperial College Ethical Review 
Committee authorized the project licence. Rats were sacrificed by cervical dislocation following exposure 
to 5% isoflurane until righting reflex was lost. Cardiac myocytes were enzymatically isolated from the left 
ventricle of healthy adult male Sprague-Dawley rats by Langendorff perfusion. Cells were attached to 
coverslips using mouse laminin (Sigma-Aldrich) and superfused with a solution containing 90 mmol/L 
KCl, 10 mmol/L NaCl, 5 mmol/L (total) K2ATP, 10 mmol/L creatine phosphate, 5.5 mmol/L (total) MgCl2, 
0.05 mmol/L K2EGTA, 0.02 mmol/L CaCl2. The fluorophore used was 5 μmol/L fluo5F pentapotassium 
salt (LifeTech) for waves and fluo4 pentapotassium salt for sparks. Cells were permeabilised in this solution 
containing 0.1 mg/ml escin (Sigma) for ~2 minutes, until Ca2+ waves were observed (denoting 
permeabilisation), whereupon cells were superfused with the original imaging solution containing varying 
concentrations of flecainide (0, 5 or 25 μmol/L). The same cell was imaged in the absence of drug (0), or 
following the addition of 5- and 25 μmol/L flecainide using a cross-over protocol. 
 
 
 
RESULTS 
 
Concentration-dependent block of cytosolic-to-luminal cation flux by flecainide. 
 
We have investigated the interactions of flecainide with individual purified, recombinant, human 
RyR2 (hRyR2) channels reconstituted into planar phospholipid bilayers under voltage clamp conditions. 
The quality of channel tetramers was determined before and after density gradient centrifugation and 
function was confirmed using Ca2+ activation (Online Figure I). As was the case in the original reports 
using native sheep cardiac RyR2,7-10 we have used a monovalent cation (K+) as the charge carrying species 
to maximize resolution of hRyR2 gating and block. With equal concentrations of K+ on both sides of the 
bilayer the direction of net K+ flux through the channel was determined by the holding potential applied 
across the bilayer. At positive holding potentials net cation flux is in the non-physiological direction, from 
the cytosolic to the luminal side of the bilayer. At negative holding potentials net K+ flux is from the luminal 
to the cytosolic side of the bilayer: equivalent to the physiological cation flux during Ca2+ release from the 
SR. As flecainide is reported to be a blocker of the open RyR2 channel,8,10 in these experiments we 
maximized channel open probability by adding EMD 4100011,15 to the solution at the cytosolic side of the 
channel. 
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Figure 1A shows current fluctuations of a representative hRyR2 channel at a holding potential of 
+40 mV (net K+ flux from cytosol to lumen) prior to, and following, the addition of increasing 
concentrations of flecainide to the solution at the cytosolic side of the membrane. In agreement with earlier 
reports,8,10 under these conditions flecainide induces short-lived, but well-resolved, transitions from the 
open state to a reduced conductance state, presumably reflecting partial occlusion of the RyR2 conduction 
pathway by flecainide. The probability of occurrence of these transitions increases as the concentration of 
flecainide is raised and with 50 μmol/L cytosolic flecainide it is clear that during each blocking event some 
K+ flux continues through the channel. 
 
Parameters of cytosolic flecainide block of cytosolic-to-luminal cation flux are quantified in Figure 
1B-D. The probability of block is dependent upon the concentration of cytosolic flecainide, with 50% of 
maximal occurrence of block at 13.1  1.9 μmol/L (where block is expressed as 1-Po, Figure 1B). Figure 
1C demonstrates that the residual current which continues to flow through RyR2 during flecainide block 
(19.2  0.6% of full conductance) is independent of flecainide concentration as would be expected if each 
blocking event occurs as the result of occupancy of a site within the conduction pathway of the channel by 
a single flecainide molecule. Consistent with this proposed mechanism, cytosolic flecainide’s interaction 
with hRyR2 can be described by a simple three state scheme (Online Figure II) in which block occurs as 
the result of a bimolecular interaction between the open channel and flecainide: 
 
 
 
As a consequence, the apparent rate constants for flecainide association with the open channel (kon), 
and its dissociation from the channel (koff), can be determined as the reciprocal of the mean dwell time in 
the open state and blocked state, respectively. It is clear from Figure 1D that, in agreement with Scheme 1, 
the rate of association of flecainide is linearly dependent on its concentration, whereas flecainide 
concentration has no influence on the dissociation of bound flecainide. 
 
The experiments presented in Figure 1 provide a detailed description of some of the mechanisms 
responsible for the partial block of cytosolic-to-luminal cation flux in hRyR2 by cytosolic flecainide, and 
confirm and extend the observations made in earlier investigations.8,10 However a rigorous assessment of 
the ability of flecainide to regulate RyR2-mediated Ca2+ release from the SR to the cytosol requires 
considerably more information.  
 
Cytosolic flecainide does not block the luminal-to-cytosolic flux of ions through hRyR2. 
  
We have investigated if the physiologically relevant flux of cations through RyR2 can be inhibited 
by cytosolic flecainide using different experimental approaches. The first of these was to monitor the action 
of cytosolic flecainide under conditions in which the net cation current through hRyR2 is driven luminal-
to-cytosolic by the trans-membrane holding potential. An example of data acquired at -40 mV is shown in 
Figure 2, where traces were obtained under conditions identical to those in Figure 1, with the holding 
potential reversed. Under these conditions cytosolic flecainide, up to a concentration of 50 μmol/L, a 
concentration in excess of the therapeutically relevant range,14 produced no significant reduction in channel 
Po.  
 
A straightforward interpretation of this observation is that cytosolic flecainide does not block the 
physiologically relevant flux of cations through RyR2. However, in addition to determining the net flux of 
cations through RyR2, trans-membrane holding potential may also directly influence the interaction of a 
blocking molecule with its binding site on the channel. Previous investigations have established that the 
Closed		Open	 Blocked 							(1) [Flec]
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effectiveness of blocking molecules, with similar modes of action to flecainide in RyR2, is increased at 
positive trans-membrane potentials.16-18 The probability of hRyR2 block by 50 μmol/L cytosolic flecainide 
was determined at holding potentials between ±70 mV (Figure 3A). These experiments demonstrate that 
the probability of block by cytosolic flecainide is influenced by trans-membrane holding potential; with 
effective block observed only at positive potentials where net cation flux through hRyR2 is cytosolic-to-
luminal. Measurements of rates of flecainide association and dissociation demonstrate that both are 
influenced by trans-membrane holding potential (Figure 3B).  
 
Voltage-dependence of block arises either as a direct result of membrane voltage on the charged 
blocking molecule or as the result of interactions between the blocker and the permeant ions.19-21 A direct 
influence of voltage on flecainide would require the blocker to be positioned within the voltage drop across 
the membrane (i.e. within the selectivity filter). It is inconceivable that a molecule as large as flecainide 
could interact at a site within the selectivity filter of RyR2, and not fully occlude the pore (a residual current 
of ~20% persists with flecainide bound (Figure 1C)). Indeed, a binding site outside the selectivity filter is 
supported by our demonstration (Online Figure III) of a direct competition between flecainide and TPeA: 
a blocking molecule with an established binding site within the cytosolic vestibule of the RyR2 pore 
forming region (PFR).22 Therefore it is logical to propose that the voltage dependence of RyR2 block by 
cytosolic flecainide arises from interactions with permeant ions within the pore. As a consequence, rather 
than blocking luminal-to-cytosolic cationic flux through RyR2, cytosolic flecainide, bound with relatively 
low affinity, will be destabilized by a net luminal-to-cytosolic flux of cations.  
 
An alternative approach is to investigate block under conditions where the driving force for ion 
movement through RyR2 is provided solely by an ionic gradient in the absence of a trans-membrane holding 
potential. Under these conditions (210 mmol/L K+ cytosolic and 850 mmol/L K+ luminal) 50 μmol/L 
cytosolic flecainide produces no blocking events to a reduced conductance level (Figure 3C), and overall 
open probability is unchanged (Figure 3D). Taken together these two experimental approaches indicate that 
flecainide at the cytosolic face of RyR2, even at a concentration 10 fold higher than that needed to reduce 
arrhythmic events in a mouse model of CPVT,10 is incapable of blocking luminal-to-cytosolic cation flux 
through the channel.  
 
Flecainide does not block hRyR2 from the luminal side of the channel. 
 
Flecainide that has crossed the sarcolemma into the cytosol will likely further equilibrate with the 
SR lumen (see Materials & Methods). Could luminal flecainide inhibit hRyR2-mediated movement of 
cations from the SR lumen to the cytosol? Figure 4A shows current fluctuations of a representative channel 
before and after the addition of 50 μmol/L flecainide to the solution at the luminal side of the channel at a 
holding potential of -40 mV, so that net K+ flux is luminal-to-cytosolic. Under these conditions no blocking 
events were observed. Figure 4B demonstrates that neither 5 nor 50 μmol/L luminal flecainide produced a 
significant reduction in hRyR2 open probability or current amplitude. These experiments establish that 
flecainide cannot enter the RyR2 PFR and block permeant cation flux from the luminal side of the channel.  
 
Flecainide does not affect hRyR2 gating. 
 
The data presented above demonstrate that the therapeutic action of flecainide in the treatment of 
CPVT does not involve block of luminal-to-cytosolic cation flux through the open channel. However, the 
physiologically relevant RyR2-mediated release of Ca2+ from the SR could be inhibited if flecainide 
reduced RyR2 open probability by an action on channel gating. We have tested this hypothesis by 
monitoring hRyR2 gating in the presence of a range of concentrations of cytosolic flecainide. In these 
experiments hRyR2 channels were activated solely by the physiological regulator of open probability, 
cytosolic Ca2+, and gating was monitored at -40 mV so that net K+ flux was luminal-to-cytosolic. Under 
these conditions flecainide produces no open channel blocking events and channels simply fluctuate 
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between open and closed gating conformations. Figure 5 demonstrates that cytosolic flecainide, up to a 
concentration of 500 μmol/L, has no significant influence on channel open probability, mean open time, 
mean closed time or single channel current amplitude. 
 
Flecainide does not block the physiologically relevant flux of Ca2+ through hRyR2. 
 
The experiments reported to this point have been carried out using K+ as the permeant cation in 
hRyR2. The use of K+ is valuable because a) it maximizes the resolution of hRyR2 gating and block and b) 
it allows manipulation of the direction of net current flow through the open channel by varying either trans-
membrane holding potential or ionic gradient, and hence provides insights into the mechanisms underlying 
the actions of flecainide in RyR2. However, in the intact cardiac muscle cell the driving force for luminal-
to-cytosolic Ca2+ flux is provided by the Ca2+ gradient across the SR membrane and during this electrogenic 
process the trans-SR membrane potential is maintained at 0 mV by charge compensating movements of 
monovalent ions through various SR membrane channels. It is possible to recreate the cytosolic and SR 
luminal ionic environments in our experiments, and to regulate RyR2 gating by including appropriate 
activating and inhibitory ligands.23,24 Figure 6A shows representative current fluctuations of a single hRyR2 
channel under these conditions. A driving force for Ca2+ movement is provided by a 100-fold (luminal-to-
cytosolic) gradient and the trans-membrane potential is clamped at 0 mV. Channel Po is regulated by the 
inclusion of cytosolic Ca2+, Mg2+ and ATP (see Materials and Methods for details). The addition of 50 
μmol/L cytosolic flecainide produces no noticeable blocking events (Figure 6A), change in current 
amplitude (Figure 6B), or significant reduction in Po (Figure 6C). 
 
Flecainide will not limit SR Ca2+ release by inhibiting the charge-compensating counter current. 
 
If flecainide does not influence Ca2+ release from the SR by modulating RyR2 function, could it 
affect SR Ca2+ release indirectly by reducing or preventing an essential charge-compensating counter 
current? 
 
Rapid, regulated, release of Ca2+ from the cardiac SR store is such a key component of cardiac 
muscle function that it is not surprising that the SR membrane is over endowed with charge compensating 
systems. Two of these involve the movement of K+ from the cytosol into the SR store in response to the 
luminal to cytosol flux of Ca2+ 23 and are hence potential targets for block by flecainide. In addition to the 
SR K+ channel, now identified as TRIC,25 RyR2 can carry a K+ counter current during Ca2+ release.23,26 The 
relative contribution of these two SR charge-compensating mechanisms during RyR2-mediated Ca2+ 
release and SERCA2a dependent Ca2+ uptake is a topic of much interest and debate.26,27  
 
We investigated the potential actions of flecainide on the SR K+ channel by incorporating isolated 
rat cardiac low-density SR membrane vesicles into planar bilayers using methods developed in our group.28 
Current fluctuations of individual channels were monitored at ±40 mV with flecainide present in the 
solutions at both sides of the bilayer. Figure 7A shows single channel current traces from a representative 
SR K+ channel at a holding potential of +40 mV. The channel shows long lasting open events which are 
unaffected by the presence of either 5 or 50 μmol/L flecainide. Subsequent addition of 2.5 mmol/L succinyl 
choline; an established blocker of the cardiac SR K+ channel,29 leads to the occurrence of characteristic 
blocking events and a reduction in channel Po (Figure 7B). As it is not possible to unequivocally determine 
the orientation of the SR K+ channel following reconstitution of isolated SR vesicles into the bilayer, we 
reversed net K+ current through the channel by imposing a holding potential of -40 mV. As was the case at 
+40 mV, flecainide produced no discernable block under these conditions (data not shown). Flecainide, 
even at very high concentrations, does not inhibit K+ movement through this charge-compensating pathway. 
 
In contrast, flecainide does reduce the charge compensating K+ counter current through RyR2. As 
established by the data presented in Figures 1-3, flecainide, present at the cytosolic face of RyR2, is a 
	DOI: 10.1161/CIRCRESAHA.116.305347      8 
concentration- and voltage-dependent partial blocker of the cytosolic-to-luminal flux of K+ through the 
open RyR2 channel. Would block of this form be sufficient to reduce the overall charge compensating 
capacity of the SR and inhibit RyR2-mediated Ca2+ release? Leaving aside the fact that, in addition to a 
counter current through RyR2, the SR membrane system has other viable charge compensating pathways; 
flecainide’s inhibition of the RyR2 counter current is not limiting. Flecainide does not fully occlude the 
RyR2 conduction pathway so that during each blocking event approximately 20% of the unblocked K+ 
current continues to flow (Figure 1C). We have calculated the reduction in RyR2-mediated K+ counter 
current resulting from block by cytosolic flecainide (Figure 7C & D). At +40 mV 50 μmol/L flecainide 
reduces RyR2 Po to ~0.75 but has a much smaller influence on total counter current, reducing it by only 
~16%. Overall it is clear that flecainide will not produce a meaningful reduction in charge compensating 
counter current during RyR2-mediated Ca2+ release from the cardiac SR. 
 
Flecainide does not block SR Ca2+ release in permeabilised rat cardiac myocytes. 
 
Measurements of the actions of flecainide on the cation conduction and gating properties of 
individual hRyR2 and SR K+ channels indicate that flecainide will not inhibit the physiologically relevant 
release of Ca2+ from cardiac SR as the result of a direct block of RyR2, or by the inhibition of charge 
compensating K+ currents through SR K+ channels and RyR2. 
 
We have tested this proposal by monitoring Ca2+ sparks and waves in individual adult rat cardiac 
myocytes, permeabilised with escin; an experimental system in which the barrier to flecainide’s access to 
the cytosol is removed, but the SR membrane network remains intact. We consider this to be the most 
reliable way of assessing SR Ca2+ release in a cell system while ensuring that there is no contribution from 
the sarcolemma; any effects seen will arise directly from an action of flecainide on the SR. Flecainide has 
no measureable effect on Ca2+ sparks (Figure 8A & B) and waves (Figure 8C & D) determined under these 
experimental conditions.  
 
 
 
DISCUSSION 
 
Flecainide, a class Ic antiarrhythmic local anaesthetic, is a well characterised use-dependent blocker 
of sarcolemmal Na+ channels that has, in recent years, been identified as a novel and effective tool in the 
treatment of patients with CPVT1 and 2. However its mechanism of action in CPVT remains controversial. 
The original reports in which the therapeutic potential of flecainide in the treatment of CPVT was 
demonstrated proposed that its primary target is the SR Ca2+ release channel, RyR2. Flecainide was reported 
to inhibit arrhythmogenic Ca2+ waves due to its ability to modulate SR Ca2+ release by blocking the open 
channel.8,10 As outlined in the Introduction, subsequent studies have highlighted alternative mechanisms of 
action for flecainide that are focussed upon its proven ability to block Na+ channels. In response to these 
investigations,11,12 it has been proposed13 that the clinical efficacy of flecainide in CPVT patients involves 
suppression of Ca2+ waves due a triple mode of action comprising a) a direct action of flecainide on 
RyR2,8,10 b) a INa-dependent reduced probability of DAD triggered action potentials as observed by Liu et 
al11 and c) a reduction in cytosolic Ca2+ concentration resulting from the change in Na+/Ca2+ homeostasis 
due to INa block as reported by Sikkel et al.12 
 
 
Given the importance of flecainide in the treatment of CPVT, and in an attempt to clarify the role 
of RyR2 in its action, we have tested the hypothesis that flecainide’s therapeutic action in CPVT patients 
is dependent upon its ability to directly modulate RyR2-mediated release of Ca2+ from the cardiac SR. Our 
data demonstrate that, while very high concentrations of cytosolic flecainide can, to some extent, block 
cytosolic-to-luminal flux of monovalent cations through RyR2, this local anaesthetic cannot inhibit the 
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physiologically relevant, luminal-to-cytosolic flux of cations through the channel or affect channel gating. 
Neither is luminal-to-cytosolic cation flux affected by high concentrations of flecainide at the luminal face 
of the channel. Moreover flecainide does not significantly inhibit the essential charge compensating 
monovalent cation counter current carried by the SR K+ channel and RyR2. Consistent with these findings 
flecainide does not inhibit RyR2-mediated Ca2+ release from the SR in permeabilised adult cardiac 
ventricular myocytes. 
 
These conclusions are based principally on observations of single hRyR2 function following 
reconstitution into planar bilayers and are therefore dependent upon the orientation of the reconstituted 
channels. RyR channels show marked structural asymmetry with clearly defined cytosolic and luminal 
domains.30,31 Given this it is inconceivable that, during reconstitution, the massive, hydrophilic, cytoplasmic 
domain would cross the membrane in preference to insertion of the much smaller, hydrophobic, trans-
membrane domain into the membrane. As a consequence, in our investigations, the cytosolic face of hRyR2 
channels will be exposed to the cis chamber and the luminal face to the trans chamber. RyR2 is also 
functionally asymmetric and experiments confirming the orientation of reconstituted channels in our study 
are presented. We show hRyR2 activation by Ca2+ in the nmol/L to μmol/L range (Online Figure I), and 
block by TPeA (Online Figure III), both of which define the cytosolic side of the channel.16,32 
 
Why doesn’t flecainide block the physiologically relevant movement of cations through RyR2? 
 
Our data establish that interactions between flecainide and RyR2 only occur when the local 
anaesthetic is added to the solution at the cytosolic side of the channel. When bound, the flecainide molecule 
adds a steric and/or electrostatic barrier to the RyR2 conduction pathway that reduces the rate of cation 
translocation from the cytosolic side of the channel to the lumen i.e. in the non-physiological direction. The 
rate at which flecainide associates with its binding site is dependent upon its concentration and, consistent 
with a simple bimolecular interaction, cytosolic flecainide concentration does not influence its rate of 
dissociation.  
 
 Both rates of association and dissociation of cytosolic flecainide are influenced by trans-membrane 
potential. The voltage drop across membrane channels is concentrated in a short, narrow, region of the PFR 
within which discrimination between ions occurs, i.e. the selectivity filter. Focusing of the voltage drop is 
made possible by intrusion of the cytosolic solution into the trans-membrane region within the large 
cytosolic vestibule of the channel,33 known to form part of K+ and Na+ channel architecture34,35 with 
equivalent structures predicted in RyR1 and RyR2.36,37 Therefore for trans-membrane potential to directly 
influence the binding site for flecainide it is logical to assume that this site would need to be within the 
region of RyR2 equivalent to the selectivity filter in K+ and Na+ channels. Modelling studies suggest that 
while this region of RyR2 is unlikely to be the sole site of ion discrimination in the channel36 it is still the 
narrowest section of the conduction pathway and will be the region over which the voltage drop occurs. 
Given this, it is highly improbable that a molecule as large as flecainide could bind within the RyR2 
selectivity filter and not fully occluding the pore. Significant residual current in the blocked state (Figure 
1C) and direct competition between flecainide and TPeA (Online Figure III) indicates that flecainide, 
entering the PFR from the cytosolic side of the channel, is bound within the cytosolic vestibule of RyR2 
and in this location does not fully occlude the pore. Our conclusion that the blocking flecainide molecule 
binds outside the voltage drop across the channel means that the observed dependence of block on trans-
membrane potential must be due to interactions between flecainide and permeant cations within the PFR. 
This conclusion is consistent with the observation that, in the absence of an applied trans-membrane 
potential, cytosolic flecainide cannot block the luminal-to-cytosolic flux of either K+ (Figure 3C and D) or 
Ca2+ (Figure 6) through RyR2. With net luminal-to-cytosolic cation flux, the affinity with which flecainide 
is bound in the cytosolic vestibule is insufficient to prevent it being displaced by interactions with permeant 
cations – a phenomenon first reported by Armstrong in K+ channels19 and recently explored in more 
detail.20,21 This, together with the observations that no blocking site for flecainide exists at the luminal face 
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of RyR2 and that flecainide has no effect on RyR2 gating, demonstrates why flecainide cannot inhibit the 
physiologically relevant movement of cations through this channel.  
 
The original proposal that the efficacy of flecainide in the treatment of CPVT resided in its ability 
to block the open RyR2 channel8,10 was bolstered by the demonstration that another IC antiarrhythmic, 
propafenone, was clinically effective in CPVT and blocked cytosolic-to-luminal cation flux in individual 
RyR2 channels in a manner equivalent to flecainide.38 However, as demonstrated in Online Figure IV, and 
consistent with our observations with flecainide, propafenone does not block the physiologically relevant, 
luminal-to-cytosol movement of cations through RyR2. In contrast, tetracaine (100-1000 μmol/L), a local 
anesthetic that is a well characterized inhibitor of Ca2+ release from the SR,39-41 decreases channel Po 
irrespective of the direction of current flow, at concentrations consistent with those used to inhibit SR Ca2+ 
release in permeablilzed cardiac myocytes.41 As demonstrated by Hilliard et al, rather than blocking the 
open channel, tetracaine reduces RyR2 Po by prolonging the duration of closed events (Online Figure V). 
These investigations demonstrate that the mechanisms of action of, on the one hand flecainide and 
propafenone, and on the other tetracaine, differ and can explain the differing abilities of these two classes 
of drug to regulate the physiological release of Ca2+ from the cardiac SR. It should be noted that a recent 
publication42 identifies a tetracaine-like ‘slow block’ effect of flecainide, which was not reported in earlier 
publications from this group.8,10,38 This new observation, which is not seen in our experiments, is still 
reported to occur during cytosolic-to-luminal cation flux through RyR2 and as a consequence, is not 
relevant to the physiological situation. 
 
The experiments on which our conclusions are based were performed on wild type human RyR2 
and some may question their relevance to the potential action of flecainide in the treatment of CPVT. Two 
lines of evidence suggest strongly that they are. Flecainide has proven to be effective in humans with, and 
animal models of, both CPVT1 and 2.7,8,11 CPVT2 is caused by disrupted control of luminal Ca2+ as a 
consequence of mutations in the Ca2+ binding protein CSQ2. Individuals with CPVT2 have wild type RyR2 
channels and these channels will respond to flecainide in the ways described in this communication. 
 
CPTV1 is caused by mutations in RyR2 and to date more than 170 different mutations have been 
identified,43 however the phenotypes of only a relatively small number of these have been examined in 
detail.44 For flecainide to block the physiologically relevant, luminal-to-cytosolic, flux of Ca2+ in these 
channels, the CPVT1 mutation, in addition to altering RyR2 function, would also have to result in a greatly 
increased affinity for flecainide in the PFR and hence prevent the destabilization of bound flecainide by 
luminal-to-cytosolic cation flux. We have investigated the actions of cytosolic flecainide on recombinant 
human RyR2 channels in which we introduced the N4104K CPVT1 mutation. Data presented in Online 
Figure VI demonstrate that the mechanisms of action of flecainide on hRyR2 are unaffected by this 
mutation. As in the wild type hRyR2, cytosolic flecainide is a concentration-dependent, partial, blocker of 
cytosolic-to-luminal cation flux, which has no effect on the luminal-to-cytosolic flux of cations.  
 
We also note that the original experiments demonstrating flecainide block of RyR2 were carried 
out using channels in sheep cardiac SR, however, we do not anticipate that species differences will affect 
the functional consequence of flecainide interaction with RyR2 as the amino acid sequences for the channel 
PFR (4731-4967) are identical in human (NP_001026.2) and sheep (XP_004021663.1). 
 
Why does flecainide inhibit movement of Na+ into the cell while failing to block the equivalent flux of 
cations through RyR2? 
 
The movement of extracellular Na+ into the cytosol during the action potential is facilitated by 
voltage sensitive, Na+ selective, channels in the sarcolemma and flecainide is a well characterised, potent, 
blocker of these channels.45,46 RyR2-mediated release of Ca2+ from the SR into the cytosol is an equivalent 
flux and the channels involved in both processes have equivalent orientations within their respective 
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membrane systems. As highlighted above, both channels have large, water-filled cytosolic vestibules and 
selectivity filter regions located towards, respectively, the extracellular and luminal end of the PFR. As is 
the case with RyR2, studies have established that block of sarcolemmal Na+ channels by flecainide results 
from interactions of these molecules, present in the cytosol, with sites in an open conformation of the 
channel.46 This raises an obvious question; if cytosolic flecainide inhibits the physiologically relevant flux 
of Na+ into the cell, why does it not inhibit the equivalent cation flux through RyR2? The answer can be 
found by an inspection of the mechanisms underlying the actions of flecainide on the two species of channel. 
As is clear from the work presented in this communication, flecainide is a simple open state, partial blocker 
of RyR2 that exerts no influence on channel gating. Block of cytosolic-to-luminal flux results from the, 
relatively low affinity, interaction of cytosolic flecainide with a site in the cytosolic vestibule of the channel. 
Flecainide at this site is rapidly displaced by luminal-to-cytosolic cation flux.  
 
Flecainide has an equivalent mode of action in the open sarcolemmal Na+ channel but exerts an 
additional influence on function. The Ca2+-dependent gating of RyR2 has been defined32 and is very 
different from the voltage-dependent gating of the Na+ channel, where the open channel must pass thorough 
structurally distinct inactivated, deactivated and closed, non-conducting, states before it can re-open. 
Cytosolic flecainide, bound in the open Na+ channel, significantly slows recovery from the inactivated and 
deactivated states47 and, as a result, prevents Na+ influx for an extended period.  
 
Conclusion. 
 
Our data demonstrate that flecainide is unable to regulate RyR2-mediated Ca2+ release from the SR 
either by directly blocking Ca2+ release through this channel or by inhibiting the charge compensating 
monovalent cation current carried by the SR K+ channel and RyR2. Flecainide is a proven use-dependent 
blocker of Na+ entry and in the absence of any evidence for an action of flecainide on the release of Ca2+ 
from the SR membrane network it is logical to propose that the Na+ channel is its primary therapeutic target 
in CPVT. Use-dependent block of INa could, in turn, reduce the probability of DADs11 and/or reduce the 
probability of RyR2 opening by reducing the level of cytosolic Ca2+ as the result of NCX-mediated Ca2+ 
efflux driven by reduced cytosolic Na+.12 
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FIGURE LEGENDS 
 
Figure 1: Flecainide partially blocks a cytosolic-to-luminal current through hRyR2. 
A. Representative single channel traces recorded at + 40 mV. Openings are downwards from the closed 
level (black line). The increase in blocking events (marked with a dotted line) with increasing flecainide 
concentration is depicted in the frequency amplitude histograms and manifests as a decrease in Po. B. The 
effect of this block on channel Po (expressed here as 1-Po, rather than Pb to emphasise change in overall 
open probability) increases with concentration. C. Residual current is unchanged with increasing flecainide 
concentration. D. Rates of association (kon) and dissociation (koff) of flecainide. Data for B-D are from n=6 
channels. 
 
Figure 2: Flecainide does not block voltage driven luminal-to-cytosolic cation flux through hRyR2. 
Representative single channel traces, recorded at – 40 mV (luminal-to-cytosolic current) in the presence of 
cytosolic flecainide. Openings are upwards from the closed level (black line), no blocking events or 
significant changes in Po were observed (n=6). 
 
Figure 3: Block is voltage dependent and does not occur when the current is driven by an ionic 
gradient in the luminal-to-cytosolic direction. A. Po of hRyR2 channels (n=6) in the presence of 50 
μmol/L cytosolic flecainide determined at holding potentials between ± 70 mV. B. Rates of association 
(kon) and dissociation (koff) are voltage dependent. C. Representative single channel traces, recorded at 0 
mV, with a luminal-to-cytosolic current provided by an ionic gradient. Openings are upwards from the 
closed level (black line). D. Po was not significantly altered by 50 μmol/L cytosolic flecainide under these 
conditions (n=3). 
 
Figure 4: Luminal flecainide does not block a luminal-to-cytosolic cation flux through hRyR2 
A. Representative single channel traces recorded at - 40 mV. Openings are upwards from the closed level 
(black line). B. No significant changes in Po or current amplitude were observed in the presence of 5 μmol/L 
(n=3) or 50 μmol/L (n=5) luminal flecainide. 
 
Figure 5: Flecainide does not affect hRyR2 gating. Luminal-to-cytosolic flux (at - 40 mV) was measured 
with Ca2+ as the sole activating ligand. Open probability, mean open and closed durations and current 
amplitude were not significantly altered by cytosolic flecainide (n=4-8). 
 
Figure 6: Flecainide does not block the physiologically relevant Ca2+ flux through hRyR2 
A. Representative single channel traces recorded at 0 mV where the driving force for Ca2+ movement is 
provided by a luminal-to-cytosolic chemical gradient. Openings are upwards from closed level (black line). 
B. Current amplitude histogram before (black) and after (red) addition of 50 μmol/L flecainide. C. Open 
probability is not significantly altered in the presence of 50 μmol/L flecainide under these conditions (n=3). 
 
Figure 7: Flecainide does not markedly inhibit the charge-compensating counter current. 
A. Representative single SR potassium channel traces recorded at + 40 mV. B. Flecainide does not block 
the SR potassium channel, but succinyl choline demonstrates characteristic block (n=5). C. Representative 
single hRyR2 traces recorded at + 40 mV, showing partial block of the cytosolic-to-luminal flux of ions 
where the reduction in counter current (C-C) has been calculated (the portion of trace underlined is 
expanded below). Openings are downwards from the closed level (solid line) D. Reduction in Po and C-C 
resulting from the partial block of hRyR2 (n=3-6). 
 
Figure 8: Flecainide does not affect SR Ca2+ release in permeabilised rat cardiac myocytes.  
Representative confocal line-scans of: A. Ca2+ sparks and C. Ca2+ waves in escin-permeabilised rat cardiac 
myocytes following the addition of flecainide at 5 and 25 mol/L. Quantitative analysis of B. Ca2+ sparks 
and D. Ca2+ waves revealed the lack of flecainide effect on any parameter. There were no statistically 
significant differences between group means as determined by ANOVA (n=19 cells).  
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Novelty and Significance 
 
 
What Is Known? 
 
 Flecainide, a class Ic anti-arrhythmic and potent Na+ channel blocker, is a clinically effective anti-
arrhythmic in individuals with catecholaminergic polymorphic ventricular tachycardia (CPVT), 
refractory to -adrenoceptor (-AR)-blockade. 
 
 In the context of CPVT, flecainide has been suggested to block of intracellular Ca2+ release through 
open cardiac ryanodine receptor (RyR2) channels. 
 
 Studies testing the effects of flecainide on RyR2 channels have focused on ion flow in the non-
physiological direction (cytosol to sarcoplasmic reticulum (SR) lumen).  
 
What New Information Does This Article Contribute? 
 
 Flecainide does not inhibit RyR2-mediated cation flow in the physiologically-relevant direction.  
 
 The primary mode of flecainide action in CPVT is Na+ channel-mediated rebalancing of 
intracellular Ca2+. 
 
 Using flecainide, and other class Ic anti-arrhythmics, as prototypical compounds is unlikely to yield 
new compounds with improved specificity for RyR2. 
 
 
CPVT is a malignant arrhythmia characterized by dysfunctional SR Ca2+ release and triggered by increased 
adrenergic drive. -AR blockers attenuate aberrant Ca2+-linked electrical activity and are the cornerstone 
of CPVT therapy. Flecainide, a class Ic anti-arrhythmic and a potent Na+-channel blocker is effective in 
CPVT patients refractory to -blockade and it has been reported that the mechanism of action is due, at 
least in part, to its direct blocking action on RyR2. We investigated the effects of flecainide on human RyR2 
in planar lipid bilayers under defined experimental conditions. Consistent with earlier reports, we show that 
flecainide blocked cation movement through the channel in the non-physiological direction. Crucially 
though, flecainide, even at supra-physiological concentrations, had no effect on the physiologically-relevant 
SR-to-cytosol cation flux through RyR2 nor did it affect other mechanisms that impinge on SR Ca2+ release 
(e.g. K+ counter current). These findings suggest that the mechanism of flecainide does not involve a direct 
action on RyR2. Our data do not negate the clinical use of flecainide but serve to highlight that class Ic 
compounds should not be considered as prototypical RyR2 blockers. 
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